Intra-Cellular Therapies Inc (BSP:I2TC34)
R$ 84.24 0 (0%) Market Cap: 52.81 Bil Enterprise Value: 46.88 Bil PE Ratio: 0 PB Ratio: 7.72 GF Score: 32/100

Intra-Cellular Therapies Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 12, 2021 / 02:10PM GMT
Jessica Macomber Fye
JPMorgan Chase & Co, Research Division - Analyst

Great. Good morning everyone. My name is Jess Fye. I am one of the senior biotech analysts at JPMorgan and we are continuing the 2021 Healthcare Conference this morning with Intra-Cellular. I'm joined by the company's CEO, Sharon Mates.

And before we get started, just wanted to remind you all that instead of moving to a breakout room this year, you'll be able to ask questions by clicking the blue 'Ask a Question' button on your screen that sends the questions to a portal. So I can ask them to management once we move into Q&A.

But with that out of the way, let me turn it over to Sharon.

Sharon Mates
Intra-Cellular Therapies, Inc. - Co-Founder, Chairman, CEO & President

Great. Thanks so much, Jess. It's a pleasure to be here. And I'm joined today by Mark Neumann, our Chief Commercial Officer; and Juan Sanchez, our Head of Investor Relations. So I'm going to go through the presentation, and I understand you all have access to it, and I'll try to remember to call

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot